3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
8
Prostatic Neoplasms
7
Leukemia, Myeloid, Acute
6
Colorectal Neoplasms
5
Breast Neoplasms
5
Stomach Neoplasms
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Erythroblastic, Acute
4
Congenital Abnormalities
4
Pancreatic Neoplasms
3
Multiple Myeloma
3
Lymphoma, Mantle-Cell
3
Lung Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Venous Thromboembolism
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Papillomavirus Infections
2
Neuroblastoma
2
Neoplasm Metastasis
2
Motor Activity
2
Melanoma
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Interventions
COVID-19 Vaccines
4
Blood Specimen Collection
4
Surveys and Questionnaires
3
Standard of Care
3
2019-nCoV Vaccine mRNA-1273
3
Pandemic Preparedness
2
sotrovimab
1
sinovac COVID-19 vaccine
1
selinexor
1
regorafenib
1
proxalutamide
1
monalizumab
1
lenzilumab
1
ciclesonide
1
bemcentinib
1
avdoralimab
1
acalabrutinib
1
XAV-19
1
Surgical Procedures, Operative
1
Sperm Count
1
Specimen Handling
1
Sorafenib
1
Sodium Chloride
1
Rabeprazole
1
Patient Reported Outcome Measures
1
Observation
1
Nutritional Status
1
Niclosamide
1
Meopa
1
Mastectomy, Segmental
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
COVID-19
×
Observation
×
Clear all
NCT04442048
2025-12-30
COV-IMMUNO
Canadian Cancer Trials Group
Phase 3
Completed
195 enrolled